This site is intended for health professionals only

Published on 29 January 2007

Share this story:
Twitter
LinkedIn

New diabetes drug recommended

teaser

Sitagliptin (Januvia), a new drug for the treatment of diabetes, has received a positive opinion from the CHMP and the EMEA, and could get full approval from the EMEA as soon as April.

This drug is the first in a new class of drugs called dipeptidyl peptidase-4 inhibitors. The FDA gave sitagliptin the green light in October 2006 as monotherapy and as add-on therapy to either metformin or thiazolidinediones to improve blood glucose control in patients with type 2 diabetes, when diet and exercise are not enough.

 



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn